NovaBay Pharmaceuticals, Inc. - Corporate Profile

Going Beyond Antibiotics!™

Developing First-In-Class Anti-Infectives
to Fight Bacteria, Viruses and Fungi

Corporate Profile

ANTI-INFECTIVE COMPOUNDS EFFECTIVE AGAINST BACTERIA, VIRUSES AND FUNGI

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds. Aganocides are novel, broad-spectrum, fast-acting, synthetic anti-infectives designed to mimic the body’s defense against infection. They are active against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.

NOVABAY’S FOUR BUSINESS UNITS

NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo and acne. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the company anticipates continuing its development of NVC-422 for the treatment of adenoviral conjunctivitis to confirm the encouraging results shown for epidemic keratoconjunctivitis (EKC) seen in the adenoviral conjunctivitis trial. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary antimicrobial solution, NeutroPhase®, which has received two 510(k) clearances from the Food and Drug Administration.

COLLABORATION WITH GALDERMA

NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications.

News and Features

January 23, 2012
NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422

January 9, 2012
NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China

November 30, 2011
NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program

November 14, 2011
NovaBay Pharmaceuticals' Aganocide Compound, NVC-422, Featured in Drugs of the Future

November 7, 2011
NovaBay Pharmaceuticals Reports Third Quarter Financial Results

October 14, 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase at the Symposium on Advanced Wound Care (SAWC)

October 4, 2011
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. As Head of Ophthalmic Drug Development

September 28, 2011
NovaBay Pharmaceuticals Names Russell A. Hoon As Vice President of its Advanced Wound Care Business Unit

September 21, 2011
NovaBay Pharmaceuticals to Present at the LD MICRO Invitational Conference

September 12, 2011
NovaBay Pharmaceuticals Reports Positive Results in Sinus Infection Study

August 25, 2011
NovaBay Pharmaceuticals Highlighted in Cataract & Refractive Surgery Today